Several non-salt and solid thienopyridine derivatives as oral P2Y₁₂ receptor inhibitors with good stability.

ID: ALA5223113

Journal: Bioorg Med Chem Lett

Title: Several non-salt and solid thienopyridine derivatives as oral P2Y₁₂ receptor inhibitors with good stability.

Authors: Liu L, Li L, Yuan J, Liu W, Li Y, Zhang S, Huang C.

Abstract: A series of novel thienopyridine derivatives were designed and synthesized as P2Y₁₂ receptor inhibitors. Several solid compounds were assessed for inhibitory effect where they exhibited stronger potency than clopidogrel. Compound 6b and 6g were evaluated for metabolism to verify that they could overcome clopidogrel resistance and for toxicity where they showed lower toxicity than prasugrel. Compound 6b exhibited lower risk of bleeding than prasugrel and showed good stability under stress testing. Overall, as a promising antiplatelet agent, representative compound 6b showed the following advantages: (1) no drug resistance for CYP2C19 poor metabolizers; (2) higher potency than clopidogrel; (3) lower toxicity than prasugrel; (4) lower risk of bleeding than prasugrel; (5) good stability as a non-salt solid.

CiteXplore: 36058469

DOI: 10.1016/j.bmcl.2022.128969

Patent ID: ┄